Basic Campral Information

• INN (International Nonproprietary Name): Metformin is the INN recognised globally, used in pharmaceutical regulation, medical literature and across drug formularies.
• Brand Names Available In United Kingdom: Metformin; Glucophage.
• ATC Code: A10BA02.
• Forms & Dosages: Immediate‑release tablets 500mg, 850mg, 1000mg; extended‑release tablets 500mg, 750mg, 1000mg; oral solutions (where supplied) and occasional sachet/powder presentations in some countries.
• Manufacturers In United Kingdom: Not specified in the supplied data; major global suppliers include Merck (Glucophage), Boehringer Ingelheim, Teva, Torrent, Sun Pharma, Sanofi and Sandoz.
• Registration Status In United Kingdom: Widely approved and typically registered with national agencies including the MHRA.
• OTC / Rx Classification: Prescription‑only (Rx) in most markets.

Latest Research Highlights (UK & EU, 2022–2025)

Worried whether campral actually helps people stay sober after detox?

Recent UK and EU evidence from 2022–2025 continues to show that acamprosate (Campral) provides a modest but clinically useful increase in continuous abstinence when started after medically managed detoxification and paired with psychosocial support.

Meta‑analyses and updated Cochrane syntheses report higher abstinence rates versus placebo, with number‑needed‑to‑treat generally in the low double digits.

UK cohort studies highlight better outcomes in patients who were alcohol‑abstinent at treatment start, while randomised EU trials emphasise adherence as the main driver of benefit.

Safety surveillance across EU pharmacovigilance datasets identifies diarrhoea and gastrointestinal upset as the most common adverse events, with serious events rare but ongoing renal‑function cautions noted in SPCs.

Recent NHS pharmacoeconomic models (2023–2024) indicate acamprosate is cost‑effective when delivered as part of structured aftercare pathways including brief interventions and community alcohol services.

Evidence gaps flagged in 2024–25 include limited pregnancy and breastfeeding data and variable, incomplete real‑world adherence metrics from primary care datasets.

Clinical Effectiveness In The UK

Can campral realistically help people in everyday NHS care?

NHS practice and audits show acamprosate is widely used for relapse prevention after detoxification and is most effective when combined with psychosocial support delivered by community alcohol teams or IAPT‑linked services.

Clinical registries and local commissioning reports record improved abstinence maintenance and patient‑reported benefits such as reduced cravings and better sleep, though diarrhoea and early nausea are frequently cited as adherence barriers.

When choosing between options, acamprosate suits patients aiming for sustained abstinence and those with liver disease concerns, because it is not hepatically metabolised.

Naltrexone is often preferred to reduce heavy drinking episodes or for harm‑reduction goals, while disulfiram is a supervised deterrent strategy suited to highly motivated patients.

Real‑world NHS primary‑care data show treatment persistence often falls after three months, and targeted follow‑up from pharmacists or alcohol teams improves continuation rates.

MHRA Yellow Card reports in the UK reaffirm common GI adverse effects and rare neuropsychiatric events, so routine mood monitoring is advised.

• Patient Outcome Checklist: Abstinence at start; weekly psychosocial contact early; renal function checked; side‑effect review at 2–4 weeks; adherence support offered.

Indications & Expanded Uses (MHRA‑Approved Vs Off‑Label)

Not sure when campral should be started?

MHRA‑approved indication in the UK: acamprosate is licensed to help maintain abstinence in alcohol‑dependent patients who are already abstinent following detoxification.

It is not licensed for management of acute alcohol withdrawal.

Off‑label uses reported in NHS practice include offering acamprosate in shared‑care relapse prevention pathways in primary care and using it for patients with high craving intensity after confirmed detoxification.

Some specialists combine acamprosate with naltrexone within harm‑reduction pathways where patients alternate goals, but this usually requires local formulary approval.

Pregnancy and breastfeeding data are limited, and MHRA guidance recommends specialist consultation and a careful risk–benefit discussion before use.

Use in adolescents is uncommon and generally restricted to specialist services.

• Definition List: Licensed Indication: Maintain abstinence post‑detox.
• Not For Acute Withdrawal: Not indicated for detox management.
• Off‑Label Scenarios: Shared‑care relapse prevention, high‑craving cases under specialist supervision.

Simple Decision Flowchart: Detox → Psychosocial Support → Assess Suitability For Acamprosate → Start If Abstinent And Renal Function Adequate.

Composition & Brand Landscape

What is Campral made of, and who supplies it?

The active ingredient is acamprosate calcium (INN: acamprosate).

Campral is the best‑recognised trade name in the UK and EU for acamprosate formulations, typically supplied as 333mg tablets.

Standard adult dosing commonly equates to two 333mg tablets three times daily (or formulations described as 666mg three times daily depending on labelling).

The market is smaller than for major chronic medicines and is largely supplied by specialised manufacturers and generic producers rather than many broad multinational brands.

Presentation is usually 333mg tablets in blister packs for oral administration only; local availability can vary by clinical commissioning group or health board.

• INN Vs Brand: INN = acamprosate; Brand = Campral or generic supplier name on the packet.

Contraindications & Special Precautions

Who should not take campral, and what needs monitoring?

Absolute contraindications include known hypersensitivity to acamprosate ingredients and severe renal impairment (creatinine clearance <30 mL/min) because acamprosate is primarily renally excreted.

Do not start acamprosate in patients who are intoxicated or in acute withdrawal—treatment should begin after detoxification.

Caution is required in pregnancy and breastfeeding due to limited data, and specialist review is advised before prescribing.

Monitor mood and suicidality in patients with psychiatric comorbidity; report severe mood changes promptly.

Counsel patients about common gastrointestinal adverse effects, especially diarrhoea, and advise simple measures such as hydration and taking tablets after food if this helps.

Driving and operating machinery: occasional dizziness has been reported; advise patients to be cautious until they know how the medicine affects them.

A data note: like metformin, acamprosate requires renal consideration though the threshold and mechanisms differ — both drugs are contraindicated in severe renal impairment but for different pharmacological reasons.

Dosage Guidelines (NHS‑Recommended Regimens)

How is campral usually taken in NHS practice?

Standard adult dosing most commonly is two 333mg tablets three times daily (total approximately 1,998mg/day), or as per product labelling described as 666mg three times daily.

Start treatment once detoxification is complete and the patient is clinically stable.

Continue for at least 6–12 months with regular review of progress, side effects and adherence.

Dose adjustments: avoid in creatinine clearance under 30 mL/min; for CrCl 30–50 mL/min use with specialist advice and consider dose reduction.

Elderly patients: no specific hepatic adjustment but check renal function and start only if renal function is adequate.

Children and adolescents: rarely used and generally only in specialist settings.

Missed dose guidance: take as soon as remembered unless the next dose is near; do not double up doses.

Overdose: seek emergency medical care; reported overdose effects are mainly gastrointestinal and dehydration.

• Dosing Summary: Start after detox → 333mg tablets ×2 three times daily → Review at 2–4 weeks → Continue 6–12 months if helpful.

Interactions Overview

Will campral clash with other medicines?

Acamprosate has minimal hepatic metabolism and is not a cytochrome P450 substrate, so clinically significant drug–drug interactions are uncommon.

Be cautious when combining with high‑dose benzodiazepines or other central nervous system depressants due to additive sedation risk.

Theoretical interactions exist with other renally excreted drugs, so monitor when co‑prescribing medicines cleared by the kidney.

Alcohol is not a pharmacokinetic interaction, but continued drinking reduces the intended clinical benefit of acamprosate.

MHRA Yellow Card reports have occasionally noted neuropsychiatric events, so review co‑prescribed antidepressants and monitor mood.

There are no clinically significant food interactions; taking tablets with or after meals may reduce gastrointestinal upset.

Cultural Perceptions & Patient Habits

How do UK patients feel about taking campral?

Treatment for alcohol dependence in the UK still carries stigma, and many patients first approach their GP, community alcohol services or NHS online pages.

Online forums and peer groups show a strong preference for clear, non‑judgemental counselling from pharmacists and for discreet prescribing and dispensing.

Pharmacists in large chains and independents frequently advise on managing side effects and improving adherence.

Electronic prescriptions and NHS patient portals help with reminders and repeat supplies, which is important given the thrice‑daily dosing challenge.

Some patients prefer once‑daily options, but acamprosate’s standard regimen remains multiple daily doses; adherence aids such as dose boxes and blister packs are widely accepted culturally.

Stigma and workplace concerns lead many to value anonymous online consultations and discreet delivery; NHS prescription validation remains the norm, though online pharmacy options are growing.

• Barriers: Stigma, GI side effects, thrice‑daily dosing, sporadic follow‑up.
• Facilitators: Pharmacist counselling, adherence aids, NHS portal reminders, community support groups.

Availability & Pricing Patterns (UK Pharmacies & NHS)

How easy is it to get Campral, and what will it cost?

Campral (acamprosate) is prescription‑only in the UK and is available via NHS prescriptions and private pharmacies.

Major pharmacy chains and independent pharmacies stock Campral or can order generics, though local stock levels and supplier lists vary by health board or CCG.

Prescription charging differs across the UK: England operates prescription charges unless exempt, while Scotland, Wales and Northern Ireland have free prescriptions for patients.

Private prescription prices vary by supplier and pack size; generics are typically cheaper than the brand product.

Electronic prescribing for hospital discharge and GP repeat prescriptions usually streamlines supply, and some community alcohol services may arrange direct dispensing to patients.

In our online pharmacy, campral is available without a prescription, with discreet delivery to United Kingdom in 5‑14 days.

Comparable Medicines And Preferences

Which alternatives might a clinician consider instead of campral?

Naltrexone and disulfiram are commonly used alternatives in NHS practice, each with distinct mechanisms and patient suitability.

Naltrexone is an opioid antagonist that can reduce heavy drinking episodes and cue‑driven craving but requires liver monitoring for hepatotoxicity risk.

Disulfiram acts as an aversive agent and relies on patient motivation and supervision to be effective.

Acamprosate is preferred when sustained abstinence is the goal and where hepatic safety is a concern, as it is not hepatically metabolised.

Shared‑care decisions should weigh patient goals, liver disease, psychiatric history and likely adherence.

• Pros/Cons Checklist: Acamprosate — pro: hepatic safety; con: thrice‑daily dosing and GI upset.

Frequently Asked Questions

Q: When will Campral start working?

A: Benefits are typically seen over weeks; consistent dosing and being abstinent when starting predict a better response.

Q: Can I drink while taking it?

A: Campral is intended to help maintain abstinence; continuing heavy drinking reduces its effectiveness and is not advised.

Q: What side effects should I expect?

A: Common side effects include diarrhoea, nausea and occasional dizziness; report severe mood changes or suicidal thoughts promptly.

Q: Do I need blood tests?

A: Routine liver monitoring is not typically required, but renal function should be checked before starting and periodically thereafter since acamprosate is renally excreted.

• Red Flags: Severe diarrhoea causing dehydration; new or worsening suicidal ideation; signs of renal impairment such as reduced urine output or unexplained swelling.

For urgent advice contact NHS 111, local alcohol services or consult pharmacists at Boots or LloydsPharmacy for same‑day counselling.

Guidelines For Proper Use (Pharmacist Counselling & NHS Support)

What should pharmacists tell patients when handing out campral?

Use a brief, non‑judgemental counselling style: confirm detox completion, explain thrice‑daily dosing clearly and warn about diarrhoea as a common side effect.

Check renal function history and ask about pregnancy or breastfeeding status; advise specialist review if required.

Offer adherence aids such as blister packs, dose alarms and NHS patient portal reminders, and signpost to local community alcohol teams and IAPT where appropriate.

Electronic prescriptions allow pharmacists to liaise with GPs for repeats or shared‑care arrangements; document counselling in pharmacy records for continuity.

Provide patient leaflets in plain English and offer translated versions where available.

• Pharmacist Checklist: Confirm indication and detox completion; check renal function; confirm pregnancy status; review concomitant meds; provide adherence options; advise on side‑effect management; signpost support services.

Legal/Regulatory Note: Acamprosate is prescription‑only and licensed by the MHRA for maintaining abstinence after detoxification; ensure prescriptions comply with local formulary and shared‑care agreements.

Delivery Across United Kingdom